TVTX

Current Thesis

FILSPARI (sparsentan) FSGS approval landed 2026-04-14 — first and only approved therapy in a ~40k US-patient orphan indication, stacked on the existing IgAN label. Six same-day PT hikes ($44–$56) cleared the tape. We are now T+8 sessions into the post-binary drift window, where rare-disease approvals either base-and-breakout into launch-ramp narrative or round-trip 20–30% as holders fade into Q1. Thesis-in-waiting, not thesis-in-motion: no fresh entry without (a) a weekly close above the 2026-04-14 gap-high on >1.5x 20-day avg volume, OR (b) the Q1 print (window ~2026-05-06 → 2026-05-13) resolving the binary on launch-readiness detail. DORMANT until one resolves. Price context is absent this refresh — do not enter blind.

Bull Case

• 2026-04-14 FDA approval for FSGS without nephrotic syndrome on 48% proteinuria reduction vs placebo (DUPLEX pivotal) — monopoly pricing power in a zero-alternative ~40k-patient US indication.
• Six sell-side PT hikes in a single session 2026-04-14: Citi $53 (Buy), Canaccord $56 (Buy), Guggenheim $54 (Buy), Wedbush $44 (Outperform), HC Wainwright $47 reiter (Buy) — clustered rerating = narrative publicly confirmed; consensus 2026/2027 revenue revisions still working through the models.
• Textbook binary-catalyst price structure 2026-04-13 17:33 ET halt → 2026-04-14 07:00 ET resumption — multi-week post-approval drift-higher is the historical base rate when launch economics are confirmed early (CRNX, KROS when ramps held vs fell apart when they didn't).
• FSGS layered on IgAN salesforce — incremental SG&A negligible; operating leverage meaningful if FSGS units materially lift the royalty base through 2026. Gross-to-net ramp on a labeled indication < 18 months is the key tell.
• LGND Q1 print ~2026-05-06 is a free read-through on FILSPARI unit velocity before TVTX itself prints — royalty-line color is the leading tell; budget to react to LGND tape BEFORE TVTX opens next session.
• Theme 'rare-disease-approvals' still tagged MATURING on our sheet 2026-04-21 — beta ride intact if group holds; would flip SATURATED on first ramp-miss in the basket.

Bear Case

• Sell-the-news is acute at T+8 sessions with zero launch data until late May 2026. KROS / CRNX historical base rate on 'approved but pre-ramp' names is a 20–30% round-trip into the first earnings print when the street has nothing to model but its own raised bar.
• No price context this refresh — we do not know where TVTX is vs the 2026-04-14 approval-day high, vs the 2026-04-13 pre-halt close, vs a 20-EMA. Trading structure-blind on a just-raised-bar name = auto-skip.
• FSGS patient ID is harder than IgAN — no biopsy-anchored diagnostic reflex, longer specialty-pharmacy cycle, risk that Q1/Q2 unit prints undershoot the freshly-inflated bar (consensus revs just happened in one session, 2026-04-14).
• Consensus revisions already in the tape — any Q1 commentary that pulls/softens 2026 FSGS guide becomes the ceiling for 6+ months. Binary risk is now 'guide', not 'approval'.
• Small/mid-cap biotech beta to XBI ~1.6 — if XBI/IBB rolls over, idiosyncratic catalysts stop mattering within ~10 sessions. Rare-disease-approvals theme goes SATURATED on the first visible ramp-miss in the basket — that's the trim trigger basket-wide.
• Our own prior decision 2026-04-19 was DEFER (6 rules / 1 ortho) — engine already flagged 'catalyst fired, wait for structure'. That signal is still live 3 sessions later.

Setup & Price Structure

Price context unavailable this refresh — operator must mark levels from the tape before any action. Required observables:

• 2026-04-14 approval-day intraday high (post-07:00 ET resumption) = sell-the-news ceiling / breakout trigger level. A weekly close above on >1.5x 20d avg volume = base-and-breakout confirmed.
• 2026-04-13 pre-halt close (17:33 ET halt print) = gap-fill invalidation. A daily close below within 15 sessions of approval = binary round-tripped, thesis dead, skip basket-wide until re-setup.
• VWAP anchored to 2026-04-14 07:00 ET resumption = bull/bear line day-to-day. Sustained trade below AVWAP = no entry, revisit post Q1 only.
• 20-EMA on daily = trim line if we ever get long. Weekly close below 20-EMA = exit, full stop.
• RSI(14) — archetype 5 (binary catalyst) does NOT use RSI>75 trim (that's a6 squeeze rule). Trim here is structural (AVWAP loss, 20-EMA weekly close below) or thesis-based (Q1 guide pull).
• Volume confirmation required — any breakout attempt on <1.0x 20d avg volume = fade, not entry. Approval-day volume is the benchmark; follow-through above it on any breakout candle is the tell.

Catalyst Calendar (next 30 days)

• ~2026-05-06 (est.) — LGND Q1 earnings. Free read-through on FILSPARI royalty line / unit ramp. Watch for: (a) royalty-revenue $ disclosed, (b) commentary on FSGS launch prep, (c) 2026 FILSPARI royalty guide change. Pre-market LGND tape the next session is the trade signal for TVTX.
• ~2026-05-06 → 2026-05-13 (est.) — TVTX Q1 2026 earnings. THE binary. Key tells: 2026 revenue guide (raised / maintained / pulled), FSGS commercial-readiness detail (salesforce sizing, payer coverage %, specialty-pharmacy onboarded count), cash burn vs launch spend. Within 3 trading days of confirmed date = earnings-blackout rule, no new longs (binary-risk deferral).
• ~2026-05-14+ (est.) — First IMS / Symphony channel-check data window for initial FILSPARI-FSGS scripts. Street's first independent read on unit velocity. Beats / misses here drive 10–15% moves historically in launch-ramp names.
• Ongoing — FDA label-clarification / REMS updates, any post-approval AdCom references (none scheduled). No PDUFA follow-ons in window.
• Theme-level — rare-disease-approvals basket members reporting through mid-May. A single ramp-miss in-basket (KROS, CRNX, IONS-adjacents) flips the theme SATURATED → basket-wide trim trigger.

What Would Change Our Mind

• To APPROVE / go long: Weekly close above the 2026-04-14 approval-day high on >1.5x 20d avg volume, AVWAP-from-resumption holding as support on pullback, AND Q1 print either already passed with raised 2026 guide or >4 trading days out. HIGH conviction unlocks only with positive LGND read-through (2026-05-06) + TVTX basing pattern intact.
• To DEFER: Current state. Catalyst fired, no price context, Q1 inside 15 sessions, no structural confirmation yet. Revisit after Q1 print or on first clean breakout candle.
• To SKIP (hard): Daily close below the 2026-04-13 pre-halt close within 15 sessions of 2026-04-14 = gap fully filled = approval round-tripped = thesis dead. Also skip if Q1 guide pulled / vague / cash burn spikes without commercial-readiness detail. Also skip basket-wide if rare-disease-approvals theme flips SATURATED on first in-basket ramp-miss.
• To TRIM (if ever long): Weekly close below 20-EMA, AVWAP-from-resumption lost on closing basis, theme flip ACCELERATING → SATURATED, or 3 trading days pre-any-catalyst. Archetype 5 trim is structural/thesis-based — NOT RSI>75 (that's a6 rule).

Correlation Notes

• Primary correlate: LGND (partner, royalty holder on FILSPARI). LGND Q1 (~2026-05-06) is a mandatory pre-read. LGND royalty-line print telegraphs TVTX unit ramp 24–72h before TVTX itself reports. Size conviction on TVTX partially off LGND tape.
• Basket: rare-disease-approvals (MATURING as of 2026-04-21). Peer tape — CRNX, KROS, IONS-adjacents — drives 30–50% of day-to-day beta in small-cap rare-disease names. A single in-basket ramp-miss flips theme SATURATED = trim basket-wide.
• Index: XBI / IBB. Small/mid-cap biotech beta ~1.6. XBI roll-over = idiosyncratic catalysts stop mattering within ~10 sessions. Monitor XBI 20-day for regime shift; risk-off rotation is the non-idiosyncratic kill switch.
• Macro: rate-sensitive via long-duration biotech factor. 10-yr yield spike = XBI drawdown = TVTX drawdown regardless of narrative. Not a trade driver but a stop-accelerator.
• No direct competitor in FSGS indication (first/only approval). Competitive read-across is IgAN-side (vs older ACE/ARB standard of care), not FSGS-side — limits downside from competitive noise.